BG62720B1 - Състав на ваксина,съдържащ конюгиран с полизахарид антиген,адсорбиран върху алуминиев фосфат - Google Patents

Състав на ваксина,съдържащ конюгиран с полизахарид антиген,адсорбиран върху алуминиев фосфат Download PDF

Info

Publication number: BG62720B1
Authority: BG; Bulgaria
Prior art keywords: vaccine; polysaccharide; adsorbed; carrier protein; hib
Prior art date: 1995-06-23

Application number

BG102146A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG102146A (en

Inventor

Julien Peetermans

Pierre Hauser

Original Assignee

Smithkline Beecham Biologicals S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-23

Filing date

1997-12-23

Publication date

2000-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG62720(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-23 Priority claimed from GBGB9512827.8A external-priority patent/GB9512827D0/en

1995-07-01 Priority claimed from GBGB9513443.3A external-priority patent/GB9513443D0/en

1995-12-15 Priority claimed from GBGB9525657.4A external-priority patent/GB9525657D0/en

1996-03-22 Priority claimed from GBGB9606032.2A external-priority patent/GB9606032D0/en

1997-12-23 Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.

1998-10-30 Publication of BG102146A publication Critical patent/BG102146A/xx

2000-06-30 Publication of BG62720B1 publication Critical patent/BG62720B1/bg

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 47
239000000427 antigen Substances 0.000 title claims abstract description 24
108091007433 antigens Proteins 0.000 title claims abstract description 24
102000036639 antigens Human genes 0.000 title claims abstract description 24
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 title claims abstract description 18
239000000203 mixture Substances 0.000 title claims abstract description 14
150000004676 glycans Chemical class 0.000 title claims description 33
229920001282 polysaccharide Polymers 0.000 title claims description 33
239000005017 polysaccharide Substances 0.000 title claims description 33
229940001007 aluminium phosphate Drugs 0.000 title abstract 2
229910000147 aluminium phosphate Inorganic materials 0.000 title abstract 2
208000015181 infectious disease Diseases 0.000 claims abstract description 6
239000003814 drug Substances 0.000 claims abstract description 3
108010078791 Carrier Proteins Proteins 0.000 claims description 15
102000014914 Carrier Proteins Human genes 0.000 claims description 15
206010043376 Tetanus Diseases 0.000 claims description 14
241000606768 Haemophilus influenzae Species 0.000 claims description 12
238000000034 method Methods 0.000 claims description 11
206010013023 diphtheria Diseases 0.000 claims description 10
229940047650 haemophilus influenzae Drugs 0.000 claims description 9
229940001442 combination vaccine Drugs 0.000 claims description 8
201000005702 Pertussis Diseases 0.000 claims description 7
102000004169 proteins and genes Human genes 0.000 claims description 7
108090000623 proteins and genes Proteins 0.000 claims description 7
241000709721 Hepatovirus A Species 0.000 claims description 5
208000000474 Poliomyelitis Diseases 0.000 claims description 5
239000002775 capsule Substances 0.000 claims description 5
229960004443 hemophilus influenzae b vaccines Drugs 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
238000002649 immunization Methods 0.000 claims description 4
230000005847 immunogenicity Effects 0.000 claims description 4
238000001179 sorption measurement Methods 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 3
230000002829 reductive effect Effects 0.000 claims description 3
230000004044 response Effects 0.000 claims description 3
239000008215 water for injection Substances 0.000 claims description 3
230000000694 effects Effects 0.000 claims description 2
239000012528 membrane Substances 0.000 claims description 2
229940028617 conventional vaccine Drugs 0.000 claims 1
244000052769 pathogen Species 0.000 claims 1
230000001717 pathogenic effect Effects 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract description 4
230000002265 prevention Effects 0.000 abstract description 3
230000006872 improvement Effects 0.000 abstract description 2
229940031348 multivalent vaccine Drugs 0.000 abstract description 2
230000002969 morbid Effects 0.000 abstract 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000004615 ingredient Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
241000700159 Rattus Species 0.000 description 4
229960000074 biopharmaceutical Drugs 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229940045808 haemophilus influenzae type b Drugs 0.000 description 3
208000005252 hepatitis A Diseases 0.000 description 3
208000002672 hepatitis B Diseases 0.000 description 3
230000003053 immunization Effects 0.000 description 3
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229940124914 Havrix Drugs 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000588650 Neisseria meningitidis Species 0.000 description 2
101710116435 Outer membrane protein Proteins 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
239000004643 cyanate ester Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
-1 1-cyano-4-dimethylamino pyridinium tetrafluoroborate Chemical compound 0.000 description 1
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
ALEBYBVYXQTORU-UHFFFAOYSA-N 6-hydrazinyl-6-oxohexanoic acid Chemical compound NNC(=O)CCCCC(O)=O ALEBYBVYXQTORU-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
229940124884 Engerix-B Drugs 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229940124915 Infanrix Drugs 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229940124909 PedvaxHIB Drugs 0.000 description 1
JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229960005097 diphtheria vaccines Drugs 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
229940124736 hepatitis-B vaccine Drugs 0.000 description 1
SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229940029583 inactivated polio vaccine Drugs 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012263 liquid product Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
229940066827 pertussis vaccine Drugs 0.000 description 1
229960005323 phenoxyethanol Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960002766 tetanus vaccines Drugs 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Biotechnology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BG102146A 1995-06-23 1997-12-23 Състав на ваксина,съдържащ конюгиран с полизахарид антиген,адсорбиран върху алуминиев фосфат BG62720B1 (bg)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB9512827.8A GB9512827D0 (en)	1995-06-23	1995-06-23	Vaccines
GBGB9513443.3A GB9513443D0 (en)	1995-07-01	1995-07-01	Vaccines
GBGB9525657.4A GB9525657D0 (en)	1995-12-15	1995-12-15	Vaccines
GBGB9606032.2A GB9606032D0 (en)	1996-03-22	1996-03-22	Vaccines
PCT/EP1996/002690 WO1997000697A1 (fr)	1995-06-23	1996-06-19	Composition de vaccin comportant un antigene polyosidique conjugue adsorbe sur du phosphate d'aluminium

Publications (2)

Publication Number	Publication Date
BG102146A BG102146A (en)	1998-10-30
BG62720B1 true BG62720B1 (bg)	2000-06-30

Family

ID=27451299

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG102146A BG62720B1 (bg)	1995-06-23	1997-12-23	Състав на ваксина,съдържащ конюгиран с полизахарид антиген,адсорбиран върху алуминиев фосфат

Country Status (35)

Country	Link
EP (2)	EP1082965B1 (fr)
JP (2)	JP4850987B2 (fr)
KR (1)	KR100425929B1 (fr)
CN (1)	CN1146444C (fr)
AP (1)	AP812A (fr)
AR (1)	AR003006A1 (fr)
AT (2)	ATE433329T1 (fr)
AU (1)	AU696338B2 (fr)
BG (1)	BG62720B1 (fr)
BR (1)	BRPI9609414B8 (fr)
CA (1)	CA2222455C (fr)
CY (1)	CY2297B1 (fr)
CZ (1)	CZ288908B6 (fr)
DE (2)	DE69612198T3 (fr)
DK (2)	DK1082965T3 (fr)
DZ (1)	DZ2055A1 (fr)
EA (1)	EA199700413A1 (fr)
EG (1)	EG25924A (fr)
ES (2)	ES2157447T5 (fr)
GR (1)	GR3036088T3 (fr)
HU (1)	HU224514B1 (fr)
IL (1)	IL122588A (fr)
MA (1)	MA23918A1 (fr)
MY (1)	MY114786A (fr)
NO (1)	NO325169B1 (fr)
NZ (1)	NZ312132A (fr)
OA (1)	OA10646A (fr)
PE (1)	PE11298A1 (fr)
PL (1)	PL184872B1 (fr)
PT (2)	PT1082965E (fr)
SI (2)	SI0833662T2 (fr)
SK (1)	SK176197A3 (fr)
TR (1)	TR199701682T1 (fr)
TW (1)	TW467746B (fr)
WO (1)	WO1997000697A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69319728T2 (de)	1992-05-23	1999-02-04	Smithkline Beecham Biologicals S.A., Rixensart	Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
US6468765B1 (en)	1995-04-21	2002-10-22	Human Genome Sciences, Inc.	Selected Haemophilus influenzae Rd polynucleotides and polypeptides
US6355450B1 (en)	1995-04-21	2002-03-12	Human Genome Sciences, Inc.	Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US6696065B1 (en)	1995-05-04	2004-02-24	Aventis Pastuer Limited	Acellular pertussis vaccines and methods of preparation thereof
IL122588A (en) *	1995-06-23	2001-12-23	Smithkline Beecham Biolog	A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies
CA2259415A1 (fr) *	1996-07-02	1998-01-08	Connaught Laboratories Limited	Vaccins dct-polio multivalents
GB9806456D0 (en) *	1998-03-25	1998-05-27	Smithkline Beecham Biolog	Vaccine composition
AU750587B2 (en) *	1998-10-16	2002-07-25	Smithkline Beecham Biologicals (Sa)	Adjuvant systems and vaccines
US6585973B1 (en)	1998-10-29	2003-07-01	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Method for preparing solid phase conjugated vaccine
GB9928196D0 (en)	1999-11-29	2000-01-26	Chiron Spa	Combinations of B, C and other antigens
GB0108364D0 (en) *	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
DK1296715T4 (en) *	2000-06-29	2016-03-07	Smithkline Beecham Biolog	Multivalent vaccine composition.
PT2332581E (pt)	2001-01-23	2015-10-16	Sanofi Pasteur Inc	Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
CN1809380B (zh)	2002-10-11	2010-05-12	启龙有限公司	广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
MXPA05004528A (es)	2002-11-01	2005-07-26	Glaxosmithkline Biolog Sa	Composicion inmunogenica.
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
ES2461350T3 (es)	2003-01-30	2014-05-19	Novartis Ag	Vacunas inyectables contra múltiples serogrupos de meningococos
GB0313916D0 (en)	2003-06-16	2003-07-23	Glaxosmithkline Biolog Sa	Vaccine composition
ATE474595T1 (de) *	2003-10-02	2010-08-15	Glaxosmithkline Biolog Sa	B. pertussis antigene und ihre verwendung bei der vakzinierung
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
NZ546430A (en)	2003-10-02	2009-04-30	Novartis Vaccines & Diagnostic	Liquid vaccines for multiple meningococcal serogroups
GB0405787D0 (en) *	2004-03-15	2004-04-21	Chiron Srl	Low dose vaccines
US9402915B2 (en)	2004-04-30	2016-08-02	Glaxosmithkline Biologicals Sa	Integration of meningococcal conjugate vaccination
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
GB0505518D0 (en)	2005-03-17	2005-04-27	Chiron Srl	Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en)	2005-03-23	2005-04-27	Glaxosmithkline Biolog Sa	Fermentation process
BRPI0610297A2 (pt)	2005-04-18	2010-06-08	Novartis Vaccines & Diagnostic	expressão de antìgeno de superfìcie de vìrus da hepatite b para a preparação de vacina
LT2351578T (lt)	2005-06-27	2017-04-10	Glaxosmithkline Biologicals S.A.	Vakcinų gavimo būdas
GB0522765D0 (en)	2005-11-08	2005-12-14	Chiron Srl	Combination vaccine manufacture
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
US10828361B2 (en)	2006-03-22	2020-11-10	Glaxosmithkline Biologicals Sa	Regimens for immunisation with meningococcal conjugates
ES2383209T3 (es)	2006-03-22	2012-06-19	Novartis Ag	Regímenes para la inmunización con conjugados meningococicos
EA015964B1 (ru)	2006-09-07	2012-01-30	Глаксосмитклайн Байолоджикалс С.А.	Вакцина
EA201490303A1 (ru)	2007-05-02	2014-05-30	Глаксосмитклайн Байолоджикалс С.А.	Вакцина
JP5637848B2 (ja)	2007-06-04	2014-12-10	ノバルティスアーゲー	髄膜炎ワクチンの製剤化
FR2918671B1 (fr) *	2007-07-10	2010-10-15	Sanofi Pasteur	Milieu de culture d'haemophilus influenzae type b.
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
GB0822633D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Formulation
TW201043267A (en) *	2009-03-19	2010-12-16	Intervet Int Bv	In situ constituting a vaccine for administration to a predetermined herd of animals
PL2411048T3 (pl) *	2009-03-24	2020-11-16	Glaxosmithkline Biologicals Sa	Adjuwantowe meningokokowe białko wiążące czynnik h
IT1398927B1 (it)	2009-06-25	2013-03-28	Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi	Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en)	2009-10-08	2009-11-25	Glaxosmithkline Biolog Sa	Expression system
RU2013136397A (ru)	2011-01-05	2015-02-10	Бхарат Байотек Интернэшнл Лимитед	Комбинированная семивалентная вакцина
GB201105981D0 (en)	2011-04-08	2011-05-18	Glaxosmithkline Biolog Sa	Novel process
TW201302779A (zh)	2011-04-13	2013-01-16	Glaxosmithkline Biolog Sa	融合蛋白質及組合疫苗
GB2495341B (en)	2011-11-11	2013-09-18	Novartis Ag	Fermentation methods and their products
DE102011122891B4 (de)	2011-11-11	2014-12-24	Novartis Ag	Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de)	2011-11-11	2014-02-13	Novartis Ag	Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
EP2592137A1 (fr)	2011-11-11	2013-05-15	Novartis AG	Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
US9475848B2 (en)	2012-02-01	2016-10-25	Glaxosmithkline Biologicals S.A.	Fermentation process for producing a virulence factor from bordetella
WO2014009971A2 (fr) *	2012-07-07	2014-01-16	Bharat Biotech International Limited	Compositions vaccinales sans alcool excluant toute origine animale et leur procédé de préparation
SG11201500573RA (en)	2012-08-06	2015-02-27	Glaxosmithkline Biolog Sa	Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en)	2012-08-06	2014-02-06	Glaxosmithkline Biologicals, S.A.	Novel method
CA2886938A1 (fr)	2012-10-12	2014-04-17	Glaxosmithkline Biologicals S.A.	Antigenes de pertussis acellulaires non reticules pour leur utilisation dans des vaccins combines
AU2014304545A1 (en)	2013-08-05	2016-02-25	Glaxosmithkline Biologicals S.A.	Combination immunogenic compositions
WO2018156465A1 (fr) *	2017-02-24	2018-08-30	Merck Sharp & Dohme Corp.	Conjugués polysaccharides-protéine utilisant le fragment b de la toxine diphtérique en tant que support
BR112020000999A2 (pt)	2017-07-18	2020-07-14	Serum Institute Of India Pvt Ltd.	composição imunogênica tendo estabilidade aperfeiçoada, imunogenicidade melhorada e reatogenicidade reduzida e processo para a sua preparação
CA3115803A1 (fr)	2018-10-12	2020-04-16	Serum Institute Of India Private Ltd.	Composition vaccinale combinee comprenant un poliovirus inactive a dose reduite et son procede de preparation
WO2020236973A1 (fr)	2019-05-20	2020-11-26	Soligenix, Inc.	Compositions et procédés de fabrication de vaccins anti-filovirus trivalents
CN111658617A (zh) *	2019-10-14	2020-09-15	四川大学	一种含铝佐剂疫苗的冻干制剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235877A (en)	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en)	1979-11-13	1983-02-08	Likhite Vilas V	Antigen compounds
IL61904A (en)	1981-01-13	1985-07-31	Yeda Res & Dev	Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4695624A (en)	1984-05-10	1987-09-22	Merck & Co., Inc.	Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
DE69113564T2 (de) *	1990-08-13	1996-05-30	American Cyanamid Co	Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en)	1990-09-28	1992-10-06	American Cyanamid Company	Oligosaccharide conjugate vaccines
AU685047B2 (en)	1992-02-11	1998-01-15	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Dual carrier immunogenic construct
DE69319728T2 (de)	1992-05-23	1999-02-04	Smithkline Beecham Biologicals S.A., Rixensart	Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
ES2126616T3 (es) *	1992-10-27	1999-04-01	American Cyanamid Co	Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna.
IL122588A (en) *	1995-06-23	2001-12-23	Smithkline Beecham Biolog	A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies

1996
- 1996-06-19 IL IL12258896A patent/IL122588A/en not_active IP Right Cessation
- 1996-06-19 DK DK00203874T patent/DK1082965T3/da active
- 1996-06-19 DK DK96922871.7T patent/DK0833662T4/da active
- 1996-06-19 SI SI9630310T patent/SI0833662T2/sl unknown
- 1996-06-19 JP JP50358197A patent/JP4850987B2/ja not_active Expired - Lifetime
- 1996-06-19 AT AT00203874T patent/ATE433329T1/de active
- 1996-06-19 AP APAP/P/1997/001159A patent/AP812A/en active
- 1996-06-19 DE DE69612198T patent/DE69612198T3/de not_active Expired - Lifetime
- 1996-06-19 DE DE69637950T patent/DE69637950D1/de not_active Expired - Lifetime
- 1996-06-19 NZ NZ312132A patent/NZ312132A/en not_active IP Right Cessation
- 1996-06-19 SI SI9630768T patent/SI1082965T1/sl unknown
- 1996-06-19 PT PT00203874T patent/PT1082965E/pt unknown
- 1996-06-19 PL PL96324242A patent/PL184872B1/pl unknown
- 1996-06-19 EP EP00203874A patent/EP1082965B1/fr not_active Expired - Lifetime
- 1996-06-19 CA CA2222455A patent/CA2222455C/fr not_active Expired - Lifetime
- 1996-06-19 WO PCT/EP1996/002690 patent/WO1997000697A1/fr not_active Ceased
- 1996-06-19 AT AT96922871T patent/ATE199831T1/de active
- 1996-06-19 CN CNB961949732A patent/CN1146444C/zh not_active Expired - Lifetime
- 1996-06-19 AU AU63591/96A patent/AU696338B2/en not_active Expired
- 1996-06-19 ES ES96922871T patent/ES2157447T5/es not_active Expired - Lifetime
- 1996-06-19 HU HU9900061A patent/HU224514B1/hu active IP Right Grant
- 1996-06-19 EP EP96922871A patent/EP0833662B2/fr not_active Expired - Lifetime
- 1996-06-19 TR TR97/01682T patent/TR199701682T1/xx unknown
- 1996-06-19 BR BRPI9609414A patent/BRPI9609414B8/pt not_active IP Right Cessation
- 1996-06-19 KR KR1019970709651A patent/KR100425929B1/ko not_active Expired - Lifetime
- 1996-06-19 CZ CZ19974189A patent/CZ288908B6/cs not_active IP Right Cessation
- 1996-06-19 PT PT96922871T patent/PT833662E/pt unknown
- 1996-06-19 ES ES00203874T patent/ES2325301T3/es not_active Expired - Lifetime
- 1996-06-19 SK SK1761-97A patent/SK176197A3/sk unknown
- 1996-06-19 EA EA199700413A patent/EA199700413A1/ru unknown
- 1996-06-21 MA MA24292A patent/MA23918A1/fr unknown
- 1996-06-21 PE PE1996000474A patent/PE11298A1/es not_active IP Right Cessation
- 1996-06-21 AR ARP960103253A patent/AR003006A1/es active IP Right Grant
- 1996-06-21 MY MYPI96002531A patent/MY114786A/en unknown
- 1996-06-22 DZ DZ960099A patent/DZ2055A1/fr active
- 1996-06-22 EG EG57496A patent/EG25924A/xx active
- 1996-06-25 TW TW085107646A patent/TW467746B/zh not_active IP Right Cessation
1997
- 1997-12-19 OA OA70169A patent/OA10646A/en unknown
- 1997-12-22 NO NO19976035A patent/NO325169B1/no not_active IP Right Cessation
- 1997-12-23 BG BG102146A patent/BG62720B1/bg unknown
2001
- 2001-06-19 GR GR20010400933T patent/GR3036088T3/el unknown
2002
- 2002-09-23 CY CY0200056A patent/CY2297B1/xx unknown
2008
- 2008-02-14 JP JP2008033301A patent/JP2008120833A/ja active Pending

Also Published As

Publication number	Publication date
JPH11507935A (ja)	1999-07-13
SI0833662T1 (en)	2001-12-31
IL122588A (en)	2001-12-23
EP0833662B1 (fr)	2001-03-21
JP4850987B2 (ja)	2012-01-11
AU696338B2 (en)	1998-09-10
WO1997000697A1 (fr)	1997-01-09
BG102146A (en)	1998-10-30
TW467746B (en)	2001-12-11
DE69612198T3 (de)	2011-08-18
HK1009764A1 (en)	1999-06-11
SI1082965T1 (sl)	2009-08-31
JP2008120833A (ja)	2008-05-29
CZ288908B6 (cs)	2001-09-12
MX9710521A (es)	1998-08-30
IL122588A0 (en)	1998-06-15
AU6359196A (en)	1997-01-22
PT833662E (pt)	2001-09-28
OA10646A (en)	2002-09-18
HU224514B1 (hu)	2005-10-28
CA2222455C (fr)	2013-05-28
EA199700413A1 (ru)	1998-08-27
KR19990028336A (ko)	1999-04-15
MA23918A1 (fr)	1996-12-31
AP812A (en)	2000-02-24
ATE199831T1 (de)	2001-04-15
HK1037516A1 (en)	2002-02-15
CN1146444C (zh)	2004-04-21
EP1082965B1 (fr)	2009-06-10
ATE433329T1 (de)	2009-06-15
CY2297B1 (en)	2003-07-04
AR003006A1 (es)	1998-05-27
NO325169B1 (no)	2008-02-11
PL184872B1 (pl)	2003-01-31
PT1082965E (pt)	2009-07-01
TR199701682T1 (xx)	1998-06-22
ES2325301T3 (es)	2009-09-01
SI0833662T2 (sl)	2011-06-30
BRPI9609414B8 (pt)	2021-05-25
NO976035L (no)	1998-02-16
BR9609414B1 (pt)	2013-11-19
DK1082965T3 (da)	2009-07-27
DE69612198D1 (de)	2001-04-26
DZ2055A1 (fr)	2002-10-20
EP0833662A1 (fr)	1998-04-08
PL324242A1 (en)	1998-05-11
DE69612198T2 (de)	2001-11-08
HUP9900061A1 (hu)	1999-04-28
HUP9900061A3 (en)	2000-03-28
MY114786A (en)	2003-01-31
ES2157447T3 (es)	2001-08-16
DK0833662T3 (da)	2001-07-09
GR3036088T3 (en)	2001-09-28
DE69637950D1 (de)	2009-07-23
CN1188418A (zh)	1998-07-22
AP9701159A0 (en)	1998-01-31
NZ312132A (en)	1999-04-29
CZ418997A3 (cs)	1998-06-17
BR9609414A (pt)	1999-05-18
NO976035D0 (no)	1997-12-22
EG25924A (en)	2012-10-22
KR100425929B1 (ko)	2004-05-31
ES2157447T5 (es)	2011-04-29
PE11298A1 (es)	1998-03-20
SK176197A3 (en)	1998-07-08
EP1082965A1 (fr)	2001-03-14
EP0833662B2 (fr)	2011-01-26
DK0833662T4 (da)	2011-02-28
CA2222455A1 (fr)	1997-01-09

Publication	Publication Date	Title
JP4850987B2 (ja)	2012-01-11	リン酸アルミニウム上に吸着したポリサッカライド結合抗原を含むワクチン組成物
JP4233113B2 (ja)	2009-03-04	多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
AU3417299A (en)	1999-10-18	Vaccine composition
US6756040B2 (en)	2004-06-29	Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminum phosphate
US20030022304A1 (en)	2003-01-30	Vaccine composition
ES2224252T3 (es)	2005-03-01	Composicion de vacuna que comprende fragmentos de la proteina de membrana externa de bordetella pertussis.
MXPA97010521A (en)	1998-11-12	A composition of vaccines including an antigen conjugated of polysaccharid adsorbided in alumi phosphate
HK1009764B (en)	2002-02-08	A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
HK1037516B (en)	2010-01-22	A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
SA96170157B1 (ar)	2005-11-12	تركيب لقاح composition vaccine يشتمل على مولد مضاد متعدد سكريد مقترن antigen conjugated polsaccharide يتم امتزازه على فوسفات الألومنيوم aluminum phosphate